Third-quarter sales were nearly $49 million, up about 53% year over year, with about $144 million in sales for the first nine months. The FDA approved Anctiva at the end of October for BCG-unresponsive papillary-only bladder cancer. A BCG-naive trial met its endpoint with a p-value of 0.01, and a supplemental application is to be submitted this year.
IBRX · ImmunityBio, Inc.
The latest filing states the doubt was alleviated.
“As a result of continuing anticipated operating cash outflows as we commercialize our approved product in the U.S. and globally and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash and cash equivalents, and investments in marketable securities; sales of our approved product; capital to be raised through equity offerings, including but not limited to, the offering, issuance and sale by us of our common stock under our Form S-3ASR shelf registration statement; and our potential ability to borrow from affiliated entities will be sufficient to fund our operations through at least the next 12 months following the issuance date of the condensed consolidated financial statements based primarily upon our Founder, Executive Chairman and Global Chief Scientific and Medical Officer’s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt.”View the 10-Q filed Nov 9, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 58%
- Last earnings
- Nov 9, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
ImmunityBio said its BCG-naive trial met its endpoint with a p-value of 0.01 and plans to submit the SBLA this year; a recent approval expanded its label to papillary-only bladder cancer.
ImmunityBio said Anctiva plus BCG met the endpoint in a BCG-naive bladder cancer trial, reporting a p-value of 0.01 and remaining on track to submit the BLA by the end of this year.
ImmunityBio reported ANKTIVA’s October 14, 2026 FDA approval for BCG-unresponsive NMIBC with high-grade papillary-only tumors and Q3 2026 net product revenue of $48.7 million, up 53% year-over-year.
ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year; FDA expanded ANKTIVA’s indication for BCG-unresponsive NMIBC, and Israel approval brought global approvals to 35.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss attributable to ImmunityBio common stockholders non-GAAP | $265.2M | the nine months ended September 30, 2026 | — |
|
|
|||
| Adjusted net loss attributable to ImmunityBio common stockholders (non-GAAP) non-GAAP | -265.17M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Cash and cash equivalents, and marketable securities | $334.3M | As of September 30, 2026 | — |
| gross-to-net adjustments | $10.2M | the three months ended September 30, 2026 filing | — |
|
|
|||
| Revenue from top four customers (share of total gross revenue) | 98% | the three months ended September 30, 2026 filing | — |
| Warrant exercises | 6,399,171 | the three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IBRX
this stock
ImmunityBio, Inc.
|
$6.40B | +204.0% | +668.3% | — | 11.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 27
Third-quarter sales were nearly $49 million, up about 53% year over year, with about $144 million in sales for the first nine months. The FDA approved Anctiva at the end of October for BCG-unresponsive papillary-only bladder cancer. A BCG-naive trial met its endpoint with a p-value of 0.01, and a supplemental application is to be submitted this year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IBRX | +0.0% | -26.8% | -16.7% | -27.4% | +204.0% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +8.6% | -17.5% | -7.6% | -18.7% | +202.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.